JP2008536855A5 - - Google Patents

Download PDF

Info

Publication number
JP2008536855A5
JP2008536855A5 JP2008506671A JP2008506671A JP2008536855A5 JP 2008536855 A5 JP2008536855 A5 JP 2008536855A5 JP 2008506671 A JP2008506671 A JP 2008506671A JP 2008506671 A JP2008506671 A JP 2008506671A JP 2008536855 A5 JP2008536855 A5 JP 2008536855A5
Authority
JP
Japan
Prior art keywords
medicament
antibody
medicament according
ibd
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008506671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008536855A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/013780 external-priority patent/WO2006113308A1/en
Publication of JP2008536855A publication Critical patent/JP2008536855A/ja
Publication of JP2008536855A5 publication Critical patent/JP2008536855A5/ja
Withdrawn legal-status Critical Current

Links

JP2008506671A 2005-04-15 2006-04-13 炎症性腸疾患（ｉｂｄ）の治療 Withdrawn JP2008536855A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67190205P 2005-04-15 2005-04-15
PCT/US2006/013780 WO2006113308A1 (en) 2005-04-15 2006-04-13 Method for treating inflammatory bowel disease (ibd) by an anti-cd20 antibody

Publications (2)

Publication Number Publication Date
JP2008536855A JP2008536855A (ja) 2008-09-11
JP2008536855A5 true JP2008536855A5 (enExample) 2009-05-28

Family

ID=36685736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008506671A Withdrawn JP2008536855A (ja) 2005-04-15 2006-04-13 炎症性腸疾患（ｉｂｄ）の治療

Country Status (16)

Country Link
US (1) US20060233797A1 (enExample)
EP (1) EP1871414A1 (enExample)
JP (1) JP2008536855A (enExample)
KR (1) KR20070122543A (enExample)
CN (1) CN101184507A (enExample)
AR (1) AR053579A1 (enExample)
AU (1) AU2006236816A1 (enExample)
BR (1) BRPI0612321A2 (enExample)
CA (1) CA2605020A1 (enExample)
IL (1) IL186151A0 (enExample)
MX (1) MX2007012667A (enExample)
NO (1) NO20075845L (enExample)
RU (1) RU2007142188A (enExample)
TW (1) TW200714291A (enExample)
WO (1) WO2006113308A1 (enExample)
ZA (1) ZA200708850B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1043312B (en) 1999-05-07 2006-07-28 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
WO2008125903A2 (en) * 2006-12-12 2008-10-23 Chaim Sheba Medical Center Method of inhibiting an undesired immune response
US7879984B2 (en) 2007-07-31 2011-02-01 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
WO2009111681A2 (en) * 2008-03-07 2009-09-11 Lawrence Bernstein Gallium compounds and methods of use to treat inflammatory bowel disease
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
EP2288719A4 (en) * 2008-05-15 2012-01-11 Univ Tufts METHOD FOR DIAGNOSIS OF CLOSTRIDIUM DIFFICILE AND METHOD AND VECTORS FOR RECOMBINANT TOXINEXPRESSION
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
AR086360A1 (es) 2011-04-21 2013-12-11 Bristol Myers Squibb Co Polipeptidos anticuerpos que antagonizan cd40
WO2013090989A1 (en) * 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN103149371B (zh) * 2013-02-26 2015-12-23 哈药慈航制药股份有限公司 生物标记物在制备预测5-氨基水杨酸治疗溃疡性结肠炎的反馈响应药物中的应用
CA2926652C (en) 2013-10-07 2021-07-20 Isotherapeutics Group, Llc High purity therapeutic bone agents
EP3113796A1 (en) * 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015350075B2 (en) 2014-11-17 2021-06-03 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using CD3xCD20 bispecific antibody
US10251933B2 (en) * 2017-04-07 2019-04-09 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
EP3654993A4 (en) * 2017-07-17 2021-08-25 The Broad Institute, Inc. CELL ATLAS OF HEALTHY HUMAN COLUMN AND HUMAN COLUMN WITH COLITIS ULCEROSA
US10738110B2 (en) * 2018-01-12 2020-08-11 Amgen Inc. PAC1 antibodies and uses thereof
IL280875B2 (en) 2018-08-31 2024-12-01 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
CN113287013B (zh) * 2019-01-04 2025-04-15 国立大学法人京都大学 溃疡性大肠炎以及原发性硬化性胆管炎的检查方法
US11535655B2 (en) * 2019-12-06 2022-12-27 Cheer Global Limited Method of treating inflammatory bowel disease
IL312692A (en) 2021-11-16 2024-07-01 Genentech Inc Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
EP1005870B1 (en) * 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6368596B1 (en) * 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
KR101023367B1 (ko) * 1998-08-11 2011-03-18 바이오겐 아이덱 인크. Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
BR9915149A (pt) * 1998-11-09 2001-08-07 Idec Pharma Corp Tratamento com anticorpo anti-cd20 quimérico de pacientes recebendo transplantes de bmt ou de pbsc
EP1035172A3 (en) * 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
EP1194167B1 (en) * 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
DE19930748C2 (de) * 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
US6100245A (en) * 1999-09-07 2000-08-08 Mcneil-Ppc, Inc. Use of simethicone to treat ulcerative colitis
WO2001034194A1 (en) * 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2001247737A1 (en) * 2000-03-24 2001-10-08 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2
US20030185796A1 (en) * 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
KR20020091170A (ko) * 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
ES2637801T3 (es) * 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
EP1286692A4 (en) * 2000-04-25 2004-11-17 Idec Pharma Corp INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF LYMPHOMAS OF THE CENTRAL NERVOUS SYSTEM
WO2001097843A2 (en) * 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
JP4731793B2 (ja) * 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
EP1383532B1 (en) * 2001-04-02 2011-05-04 Genentech, Inc. Combination therapy
ATE443259T1 (de) * 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
US20030157108A1 (en) * 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2476166C (en) * 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219818A1 (en) * 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
PL216630B1 (pl) * 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
ES2347241T3 (es) * 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
EP2062916A3 (en) * 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
RU2370775C2 (ru) * 2003-07-29 2009-10-20 Дженентек, Инк. Анализ нейтрализующих антител и его применение
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR20060132554A (ko) * 2003-08-29 2006-12-21 제넨테크, 인크. 안과 질병의 항-ｃｄ２０ 치료
MXPA06006864A (es) * 2003-12-19 2006-08-23 Genentech Inc Deteccion de cd20 en la terapia de enfermedades autoinmunes.
ZA200608982B (en) * 2004-05-05 2008-06-25 Genentech Inc Preventing autoimmune disease by using an anti-CD20 antibody

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity

Similar Documents

Publication Publication Date Title
JP2008536855A5 (enExample)
Tanida et al. Adalimumab for the treatment of Japanese patients with intestinal Behçet’s disease
Serrano et al. Use of infliximab in pediatric patients with inflammatory bowel disease
RU2007142188A (ru) Способ лечения воспалительного заболевания кишечника (взк) анти-cd-20 антителом
EP4212160A1 (en) Use of chiauranib in combination with immune checkpoint inhibitor in antitumor therapy
Saneeymehri et al. Overview of pharmacological treatment options for pediatric patients with refractory Kawasaki disease
CN105263579B (zh) 左西替利嗪和孟鲁司特在治疗血管炎中的用途
McCormack et al. Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease
Cho et al. Clinical characteristics of angioedema with eosinophilia
Zavaleta-Monestel et al. Advances in systemic lupus erythematosus treatment with monoclonal antibodies: a mini-review
Actis et al. Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease
JPWO2019016928A1 (ja) がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤
Panahi et al. Hepatotoxicity secondary to levofloxacin use
CN111195249B (zh) 西达本胺联合r-chop的应用及联合药物
Jeong et al. A case of severe HIV-associated psoriasis successfully treated with acitretin therapy
Owens New FDA drug approvals hit an 18-year high in 2014
Baldwin et al. Managing pediatric Crohn’s disease: recent insights
CN110831590A (zh) 含有培马贝特的医药
Mamula et al. Biological and novel therapies for inflammatory bowel disease in children
Dodds Drugs in use: clinical case studies for pharmacists
Howell Ulcerative colitis: achieving and maintaining remission
Ebied et al. 2017 is banner year for drug approvals by the Food and Drug Administration
EP4616867A1 (en) Combination of endothelin receptor antagonist and glucocorticoid for treating iga nephropathy
JP6802598B1 (ja) 抗がん剤の効果増強剤
Feagan Medical management of ulcerative colitis in 2006: What's on the horizon?